Table 1.
VEGF/Anti-VEGF Alters the Expression of Many Members of the Wnt Pathway
| Group | Statistically Significant Difference | No Statistically Significant Difference |
|---|---|---|
| Group 1: altered by VEGF; reversed by anti-VEGF | Control vs. VEGF VEGF vs. anti-VEGF | |
| Group 2: altered by VEGF; Not reversed by anti-VEGF | Control vs. VEGF | VEGF vs. anti-VEGF Control vs. anti-VEGF |
| Groups 3: altered by VEGF; altered by anti-VEGF in the same direction as VEGF | Control vs. VEGF VEGF vs. anti-VEGF | |
| Group 4: not altered by VEGF; altered by anti-VEGF | Control vs. anti-VEGF | Control vs. VEGF |
| The table indicates the types of comparisons that were the basis for the four groups. | ||
| Group 1 : Altered by VEGF; R eversed by A nti-VEGF | ||
| Gene Name | VEGF R esponse | Anti-VEGF R esponse |
| DKK1 | ↓ (P = 0.000) | ↑ (P = 0.000) |
| DKK2 | ↑ (P = 0.000) | ↓ (P = 0.000) |
| DKK3 | ↑ (P = 0.038) | ↓ (P = 0.020) |
| FZD1 | ↑ (P = 0.000) | ↓ (P = 0.004) |
| FZD8 | ↓ (P = 0.008) | ↑ (P = 0.000) |
| LRP5 | ↑ (P = 0.014) | ↓ (P = 0.017) |
| PSEN2 | ↑ (P = 0.000) | ↓ (P = 0.000) |
| CACYBP | ↓ (P = 0.045) | ↑ (P = 0.033) |
| CTNNB1 | ↑ (P = 0.000) | ↓ (P = 0.000) |
| JUN | ↓ (P = 0.000) | ↑ (P = 0.004) |
| FOSL1 | ↓ (P = 0.000) | ↑ (P = 0.007) |
| CCND2 | ↑ (P = 0.000) | ↓ (P = 0.001) |
| Group 2 : Altered by VEGF; N ot R eversed by A nti-VEGF | ||
| WNT10B | ↓ (P = 0.005) | |
| WNT2B | ↑ (P = 0.043) | |
| SFRP1 | ↓ (P = 0.011) | |
| FZD6 | ↑ (P = 0.002) | |
| CSNK1G2 | ↓ (P = 0.034) | |
| CSNK2A1 | ↓ (P = 0.003) | |
| DVL1 | ↓ (P = 0.001) | |
| AXIN1 | ↓ (P = 0.015) | |
| AXIN2 | ↑ (P = 0.022) | |
| PRKACA | ↓ (P = 0.023) | |
| PTPA | ↓ (P = 0.005) | |
| SKP1 | ↑ (P = 0.000) | |
| TBL1X | ↓ (P = 0.000) | |
| CTNNBIP1 | ↑ (P = 0.031) | |
| RBX1 | ↑ (P = 0.000) | |
| RUVBL1 | ↓ (P = 0.002) | |
| SMAD3 | ↓ (P = 0.000) | |
| CITED2 | ↑ (P = 0.028) | |
| TCF3 | ↓ (P = 0.003) | |
| TCF7 | ↓ (P = 0.016) | |
| TCF20 | ↓ (P = 0.020) | |
| TLE3 | ↓ (P = 0.013) | |
| MYC | ↓ (P = 0.001) | |
| Group 3 : Altered by VEGF; A ltered by A nti-VEGF in the S ame D irection as VEGF | ||
| CREBBP | ↓ (P = 0.029) | ↓ (P = 0.042) |
| CCND1 | ↓ (P = 0.000) | ↓ (P = 0.000) |
| TCF4 | ↑ (P = 0.002) | ↑ (P = 0.030) |
| Group 4 : N ot A ltered by VEGF; A ltered by A nti-VEGF | ||
| TLE2 | ↑ (P = 0.000) | |
| FZD2 | ↓ (P = 0.042) | |
| FZD4 | ↓ (P = 0.000) | |
| FZD5 | ↓ (P = 0.013) | |
| LRP6 | ↓ (P = 0.011) | |
Our previous RNAseq results showed that VEGF (1 nM) significantly altered (P < 0.05) expression of 4372 genes, and anti-VEGF (aflibercept, 500 nM) overcame the effect of VEGF for 279 of these genes in HG HRECs.7 Table 1 shows the subset of the data, which are members of Wnt pathway. The changes in expression between experimental groups is the basis for inclusion in a specific group.